<DOC>
	<DOCNO>NCT00241111</DOCNO>
	<brief_summary>Study determine effectiveness safety zoledronic acid whether pharmaco-economic impact prostate cancer bone metastasis .</brief_summary>
	<brief_title>Assessment Efficacy , Tolerability Pharmaco-economic Impact Zoledronic Acid Treatment Prostate Cancer With Bone Metastasis</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Aged ≥18 year . Written informed consent . With histologicallyproven prostate carcinoma . ECOG performance status ≤ 2 Life expectancy &gt; 12 month Current previously document diagnosis least 1 bone metastasis due prostate cancer ( patient could hormono naif , Hormono sensible hormono refractory ) Patients partner childbearing potential use barrier method contraception throughout study . ECOG performans status &gt; 3 Prior treatment bisphosphonates IV within last 3 month study Renal insufficiency ( serum creatinine &gt; 265 micromol/L &gt; 3.0 mg/dL ) Liver function test &gt; 2.5 ULN Patients another nonmalignant disease would confuse evaluation primary endpoint prevent patient comply protocol . History concomitant disease influence bone metabolism Paget 's disease primary hyperparathyroidism Disabling non control concomitant disease likely alter quality life Patient unable fill questionnaire : senile dementia , psychiatric neurological disease , illiterate partially sighted patient Known hypersensitivity zoledronic acid bisphosphonates Other protocoldefined inclusion / exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Prostate</keyword>
	<keyword>cancer</keyword>
	<keyword>bone metastasis</keyword>
	<keyword>zoledronic acid</keyword>
</DOC>